Klinička farmakologija levotiroksina i antitiroidnih lekova

  • Radica Stepanović-Petrović Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmakologiju
  • Maja Tomić Univerzitet u Beogradu – Farmaceutski fakultet, Katedra za farmakologiju
DOI: https://doi.org/10.5937/arhfarm72-40086
Ključne reči: Hašimotov tiroiditis, Grejvsova bolest, levotiroksin, tiamazol, propiltiouracil

Sažetak


Najčešća oboljenja štitaste žlezde su autoimune bolesti praćene razvojem hipotiroidizma (Hašimotov tiroiditis) i hipertiroidizma (Grejvsova bolest). Hipotiroidizam je klinički sindrom koji nastaje kao posledica deficita tiroidnih hormona. Hipertiroidizam je preterana aktivnost tiroidne žlezde praćena hipersekrecijom tiroidnih hormona. Pojednostavljeno, za postizanje eutiroidnog stanja u oba klinička sindroma se koriste (najčešće) dva leka – levotiroksin (hipotiroidizam) i tioamid (hipertiroidizam). Naizgled je jednostavno, ali zapravo tokom lečenja, koje je u slučaju hipotiroidizma doživotno, treba pažljivo pratiti pacijente uz prilagođavanje doze leka i uključivanje drugih lekova za lečenje komorbiditeta.

Reference

1.      Brent GA, Koenig RJ. Thyroid and antithyroid drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018; p. 787-801.

2.      Brayfield A. Martindale: The complete drug reference. 39th ed. London: Pharmaceutical press; 2017.

3.      Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457-69.

4.      Topliss DJ, Eastman CJ. 5: Diagnosis and management of hyperthyroidism and hypothyroidism. Med J Aust. 2004;180(4):186-93.

5.      Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24:1670-751.

6.      Jameson JL, Mandel SJ, Weetman AP. Hypothyroidism. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill Companies; 2018; p. 2698-703.

7.      Vaidya B, Pearce SH. Management of hypothyroidism in adults. BMJ. 2008;337:a801.

8.      Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38.

9.      Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351(3):241-9.

10.  Preston CL. Stockley’s Drug Interactions, 12th ed. London: Pharmaceutical Press; 2019.

11.  Aanderud S, Myking OL, Strandjord RE. The influence of carbamazepine on thyroid hormones and thyroxine binding globulin in hypothyroid patients substituted with thyroxine. Clin Endocrinol (Oxf). 1981;15:247-52.

12.  Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2015;82:136-41.

13.  Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18:293-301.

14.  Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med. 1994;97:363-5.

15.  Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26:1343-1421.

16.  Jameson JL, Mandel SJ, Weetman AP. Hyperthyroidism. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill Companies; 2018; p. 2703-10.

17.  Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7:167-186.

18.  Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185:G43-G67.

Objavljeno
2022/10/31
Broj časopisa
Vol. 72 Br. Notebook 5 (2022): Arhiv za farmaciju
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).